U.S. Markets close in 5 hrs 15 mins

SciClone Pharmaceuticals, Inc. (SCLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.12+0.02 (+0.23%)
As of 10:44AM EDT. Market open.
People also watch

SciClone Pharmaceuticals, Inc.

950 Tower Lane
Suite 900
Foster City, CA 94404
United States

IndustryDrug Manufacturers - Other
Full Time Employees570

Key Executives

Dr. Friedhelm Blobel Ph.D.CEO, Pres & Exec. Director1.17M9.57M68
Mr. Wilson W. CheungCFO & Sr. VP of Fin.799.97k612.96k48
Mr. Hong ZhaoChief Exec. Officer of China Operations935.79kN/A54
Ms. Lan XieVP of Fin. & CFO of China Operations494.9k137.51k44
Mr. Carey ChernChief Compliance Officer, Gen. Counsel & Corp. Sec.N/AN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, Angiomax, and Cleviprex. The company has a strategic partnership with The Medicines Company to promote Angiomax (bivalirudin) and Cleviprex (clevidipine). SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.

Corporate Governance

SciClone Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 1. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.